on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital
On March 17, 2026, Heights Capital Management, Inc., through CVI Investments, Inc., announced that it had crossed the 5% threshold of share capital and voting rights in GENSIGHT BIOLOGICS SA. The investment reached 8.42% of the share capital. This transaction follows a capital increase.
Heights Capital holds 58,488,704 warrants, exercisable until their maturity date. These warrants allow the purchase of additional shares of GENSIGHT BIOLOGICS. The company also holds 120 convertible bonds, representing a maximum of 29,031,664 shares based on the price as of March 12, 2026.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news